Mumbai, Feb. 28 -- Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names Liraglutide Biocon for diabetes (gVictoza(R)) and Biolide for chronic weight management (gSaxenda(R)).

Published by HT Digital Content Services with permission from Capital Market....